Zydus receives final approval from the USFDA for Acyclovir Ointment & Lurasidone Hydrochloride

Zydus receives final approval from the USFDA for Acyclovir Ointment & Lurasidone Hydrochloride

Zydus Cadila has received the final approval from the USFDA to market Acyclovir Ointment USP (US RLD – Zovirax®), 5%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. Acyclovir is an antiviral drug which stops the growth of certain viruses. This medication is used to treat the first outbreak of genital herpes infection. It is also used to treat non-lifethreatening herpes infections of the skin and around the mouth (cold sores) in people with a weakened immune system. The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila has also received the final approval from the USFDA to market Lurasidone Hydrochloride Tablets USP (US RLD – Latuda Tablets), in the strengths of 20 mg, 40 mg, 60 mg, 80 mg and 120 mg. It will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad. The medication is used to treat certain mental/mood disorders such as schizophrenia, depression associated with bipolar disorder. It may also help to decrease hallucinations (hearing/seeing things that are not there). The group now has 257 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.